OLFM4 Protein, Human (HEK293, His)

1 Cited Publications
Customer Review

Based on 1 publication(s) in Google Scholar

OLFM4 protein may promote the proliferation of pancreatic cancer cells by affecting the transition from S phase to G2/M phase, highlighting its role in cancer cell cycle dynamics. In myeloid leukemia cell lines, OLFM4 exhibits dual effects of inhibiting growth and inducing differentiation and apoptosis. OLFM4 Protein, Human (HEK293, His) is the recombinant human-derived OLFM4 protein, expressed by HEK293 , with C-10*His labeled tag.

For research use only. We do not sell to patients.
  • Species: Human
  • Source: HEK293
  • Storage:
    Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
  • Biological Activity
  • Technical Parameters
  • Product Properties
  • Documentation
  • Help & FAQs

Biological Activity

Description

OLFM4 protein may promote the proliferation of pancreatic cancer cells by affecting the transition from S phase to G2/M phase, highlighting its role in cancer cell cycle dynamics. In myeloid leukemia cell lines, OLFM4 exhibits dual effects of inhibiting growth and inducing differentiation and apoptosis. OLFM4 Protein, Human (HEK293, His) is the recombinant human-derived OLFM4 protein, expressed by HEK293 , with C-10*His labeled tag.

Background

OLFM4 Protein is implicated in potentially promoting the proliferation of pancreatic cancer cells by facilitating the transition from the S to G2/M phase, underscoring its potential role in the cell cycle dynamics of cancerous cells. Conversely, in myeloid leukemic cell lines, OLFM4 inhibits cell growth while inducing cell differentiation and apoptosis, indicating its dual role in distinct cellular contexts. Additionally, it may contribute to the inhibition of EIF4EBP1 phosphorylation/deactivation, suggesting a potential role in modulating protein translation processes. OLFM4 is known to facilitate cell adhesion, possibly through interactions with cell surface lectins and cadherin. Structurally, OLFM4 exists as a homomultimer with disulfide linkages. It interacts with NDUFA13 and exhibits binding affinity to cell surface lectins, including locutions ricinus communis agglutinin I, concanavalin-A, and wheat germ agglutinin, along with cadherin. The multifaceted functions and interactions of OLFM4 highlight its significance in cellular processes with implications in cancer progression and cell adhesion. Further research is crucial to unravel the precise molecular mechanisms through which OLFM4 modulates diverse cellular functions.

Verified Bioactivity

Measured by the ability of the immobilized protein to support the spreading of NIH3T3 mouse embryonic fibroblast cells. The ED50 for this effect is 0.625-1.25 μg/mL, corresponding to a specific activity is 800-1600 U/mg.

Technical Parameters

  • Species Human
  • Source HEK293
  • Tag C-10*His
  • Accession
  • Gene ID
  • Molecular Construction
    • N-term
    • OLFM4 (D21-Q510)
      Accession # Q6UX06
    • 10*His
    • C-term
  • Protein Length

    Full Length of Mature Protein

  • Synonyms

    OLFM4; Olfactomedin-4; Olfactomedin 4; Olfactoimedin; GW112; Tiarin; OlfD; HGC-1; PDP4; HOLfD; GC1; OLM4; G-CSF-Stimulated Clone 1 Protein; BA209J19.1; Antiapoptotic Protein GW112; UNQ362

  • AA Sequence

    DLGDVGPPIPSPGFSSFPGVDSSSSFSSSSRSGSSSSRSLGSGGSVSQLFSNFTGSVDDRGTCQCSVSLPDTTFPVDRVERLEFTAHVLSQKFEKELSKVREYVQLISVYEKKLLNLTVRIDIMEKDTISYTELDFELIKVEVKEMEKLVIQLKESFGGSSEIVDQLEVEIRNMTLLVEKLETLDKNNVLAIRREIVALKTKLKECEASKDQNTPVVHPPPTPGSCGHGGVVNISKPSVVQLNWRGFSYLYGAWGRDYSPQHPNKGLYWVAPLNTDGRLLEYYRLYNTLDDLLLYINARELRITYGQGSGTAVYNNNMYVNMYNTGNIARVNLTTNTIAVTQTLPNAAYNNRFSYANVAWQDIDFAVDENGLWVIYSTEASTGNMVISKLNDTTLQVLNTWYTKQYKPSASNAFMVCGVLYATRTMNTRTEEIFYYYDTNTGKEGKLDIVMHKMQEKVQSINYNPFDQKLYVYNDGYLLNYDLSVLQKPQ

  • Molecular Weight

    Approximately 60-90 kDa, based on SDS-PAGE under reducing conditions.

  • Purity

    ≥ 80%, as determined by reducing SDS-PAGE.

Product Properties

Appearance

Lyophilized powder.

Formulation

1.Lyophilized from a 0.22 μm filtered solution of PBS, 5% trehalose, pH 7.4.
2.Lyophilized from a 0.22 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4.
Please refer to the lot-specific COA for specific buffer information.

Endotoxin Level

<1 EU/μg, determined by LAL method.

Reconstitution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O.

Storage & Stability

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US;may vary elsewhere.

Calculators

Reconstitution Calculator

Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration

Volume (to add to vial) Volume (to add to vial)
=
Mass (in vial) Mass (in vial)
÷
Desired Reconstitution Concentration Desired Reconstitution Concentration
Dilution Calculator

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

Concentration (start) Concentration (start)
×
Volume (start) Volume (start)
=
Concentration (final) Concentration (final)
×
Volume (final) Volume (final)
The Specific Activity Calculator Equation
  • Specific Activity (Unit/mg)
  • Biological Activity (ED50)

Specific Activity (Unit/mg) = 106 ÷ Biological Activity (ED50)

Specific Activity (Unit/mg) Specific Activity (Unit/mg)
Unit/mg
= 106 ÷
Biological Activity (ED50) Biological Activity (ED50)
106 ÷
ng/mL
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00